

Appl. No. : Unknow
Filed : Herewith

Sub E4 6. (Amended) A method according to [any one of] claim[s] 1 [to 5] wherein the viral infection is a hepatitis infection or other viral infection of the human or animal liver.

7. (Amended) A method according to [any one of] claim[s] 2 [to 6] wherein said cell is a liver cell.

8. (Amended) ~~A substance identified by the method of [any one of the preceeding claims]~~ claim 1.

13. (Amended) ~~[A] An isolated polynucleotide encoding a protein according to claim 11 [or 12 sequence for use in affecting a viral infection].~~

14. (Amended) ~~A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of] a protein according to claim 11 [or 12, or a polynucleotide according to claim 13 in the manufacture of a medicament for use in affecting a viral infection], and a pharmaceutically acceptable non-toxic vehicle.~~

15. (Amended) ~~A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of a substance in the manufacture of a medicament for use in affecting a viral infection, wherein the]a substance [has been] identified by the method of [any one of] claim[s] 1 [to 7], and a pharmaceutically acceptable non-toxic vehicle.~~

16. (Amended) ~~A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of a substance in the manufacture of a medicament for the use in affecting a viral infection wherein said]a substance which can upregulate expression of ADRP in a mammalian cell, and a pharmaceutically acceptable non-toxic vehicle.~~

Please delete Claim 9.

Please add the following claims:

Sub E5 17. A method according to claim 5 wherein the viral infection is a hepatitis infection or other viral infection of the human or animal liver.

18. A method according to claim 5 wherein said cell is a liver cell.

19. ~~A substance identified by the method of claim 5.~~

20. A pharmaceutical composition for treating viral infections in a mammal, comprising a polynucleotide according to claim 13 in the manufacture of a medicament for use in affecting a viral infection, and a pharmaceutically acceptable non-toxic vehicle.